Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma (MYELOCHOL)

  • STATUS
    Recruiting
  • participants needed
    30
  • sponsor
    University Hospital, Bordeaux
Send
Updated on 3 December 2023
See if I qualify

Summary

Multiple myeloma (MM) survival has been improved during the last decade owing to new treatments. Hence, it has become a matter of importance to precisely define the depth of MM response to therapy. 18F-FDG PET/CT (FDG-PET) has proved to be superior to X-rays for the initial staging of MM. It is now recommended by the International Myeloma Working Group (IMWG) during the initial work-up and for response evaluation, as it is superior to MRI in that setting. However, sensitivity of FDG-PET remains inferior to that of MRI for the initial staging of MM. Indeed, FDG-PET remains limited for the evaluation of skull lesions (due to brain physiological background) or spine infiltrative disease. Therefore, there is a need for a new diagnostic tool which could have equivalent sensitivity to that of MRI at diagnosis, and could bring better baseline information than FDG PET for therapy evaluation. Ultimately, this tool would be a one-stop-shop exam for diagnosis and patient follow-up during treatment. 18F-Choline, a tracer of phospholipids of cell membrane, has shown potential as compared to 18F-FDG in a recent retrospective study, with about 70% more lesions detected in MM patients with suspected relapsing disease. Following that perspective, our main objective is to compare prospectively, in a cohort of newly diagnosed MM, the detection rate of MM lesions by 18F-Choline PET/CT (FCH-PET) vs. FDG-PET. Our secondary objectives will be to compare the performance of both PET modalities as regard to MRI as well as the detection rate of extra-medullary lesions. Patients with MM will proceed to FCH-PET, FDG-PET and then Whole-Body MRI within 3 weeks.

Description


Details
Condition Myeloma Multiple
Age 18years or above
Treatment Positron Emission Tomography using 18F-FCH, Positron Emission Tomography using 18F-FDG
Clinical Study IdentifierNCT03891914
SponsorUniversity Hospital, Bordeaux
Last Modified on3 December 2023

Eligibility

 Yes No Not Sure

Inclusion Criteria

Symptomatic Multiple Myeloma on first-line treatment as defined by 2014 International Myeloma Working Group criteria
Measurable disease either by serum or urinary monoclonal protein level or by serum free light chains assay
Age > 18 years old at time of signed consent
Beneficiary of social security insurance
Signed informed consent

Exclusion Criteria

Previous Multiple Myeloma treatment
Previous cancer with less than 5 year of complete remission (including plasmacytoma)
Chemotherapy in the 6 months preceding the inclusion
Uncontrolled diabetes mellitus
Medullary growth factor injection less than 48 hours before imaging procedures
Ongoing corticosteroid therapy, or given less than 72 hours before PET-CT imaging
Pregnant or nursing (lactating) women
Childbearing potential woman without adequate barrier contraception method (HAS criteria)
Freedom deprivated patient by judiciary or administrative decision
Patient under legal protection or unable to express its own consent
PET contraindication (known allergy to 18F-FCH or 18F-FDG or excipient)
MRI contraindication
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.